Chemotherapy Research and Practice / 2012 / Article / Fig 2

Review Article

Advances in Targeting HER3 as an Anticancer Therapy

Figure 2

Mechanisms by which HER3 contributes to resistance to EGFR-targeted therapy. (a) The oncogenic receptor tyrosine kinase MET could phosphorylate HER3, leading to activation of the PI3 K/Akt pathway independent of EGFR kinase activity [57]. (b) Lengthy exposure of cancer cells to TKIs can lead to Akt downregulation which consequently increases HER3 translocation from the cytoplasm to the membrane through a feedback regulation. The phosphorylation of HER3 recruits PI3 K and further activates the PI3 K/Akt pathway which plays an important role in resistance to EGFR-targeted therapy [2].

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.